PK and virologic response relationships have mainly been evaluated in antiretroviral na´ve patients
- Prior approvals with efficacy, safety and PK data have focused on na´ve patients
1D. Are these relationships applicable to treatment experienced patients?
Are there cases where additional PK and/or efficacy data are necessary for different patient populations?